SCHEMBL3767559

SCHEMBL3767559

O=C(CN1CCN(c2cccc(C(F)(F)F)n2)CC1)N1CCN(C2CCC2)CC1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 6/20 0.49
DRD2 P14416 6/20 0.48
DRD3 P35462 6/20 0.48
HRH3 Q9Y5N1 5/20 0.47
HTR1A P08908 3/20 0.47
OPRM1 P35372 1/20 0.46
DRD4 P21917 2/20 0.45
HTR2A P28223 2/20 0.45
HTR2C P28335 2/20 0.45
HTR2B P41595 2/20 0.45
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPT P10636 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3859907 0.82 HRH3 (0.51) HRH3MEN1ALDH1A1KMT2A
SCHEMBL3972995 0.82 HRH3 (0.55) DRD2DRD3HRH3HTR1AOPRM1
SCHEMBL3771336 0.80 SMN1; SMN2 (0.54) HRH3MEN1ALDH1A1MAPTKMT2A
SCHEMBL3762865 0.78 POLB (0.61) MEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL3773673 0.78 SMN1; SMN2 (0.54) HRH3MEN1ALDH1A1MAPTKMT2A
SCHEMBL3777238 0.78 SMN1; SMN2 (0.53) HRH3MEN1ALDH1A1MAPTKMT2A
SCHEMBL3773835 0.78 ME2 (0.55) HRH3MEN1ALDH1A1MAPTKMT2A
SCHEMBL13004950 0.78 ALDH1A1 (0.63) HRH3ALDH1A1MAPTKMT2ASMN1; SMN2
SCHEMBL3770274 0.77 CNR2 (0.52) MEN1ALDH1A1MAPTKMT2ASMN1; SMN2
SCHEMBL3769780 0.77 ALDH1A1 (0.51) HRH3MEN1ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 IRAK4 862/4885DRD2 473/4885DRD3 569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.